Clinical Trial Update: Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of elacestrant and exemestane in pretreated HR+/HER2- metastatic breast cancer; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Elacestrant (elacestrant)
• Exemestane (Exemestane)

Snippet

Sponsor: European Institute of Oncology | Conditions: Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING